SAN DIEGO, Sept. 12, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Lazard Capital Markets Corporate Access Day in Boston, Mass., and the Credit Suisse 3rd Annual Small and Mid-Cap Conference, in New York.
On Tuesday, September 18, Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will participate in the Lazard Capital Markets Corporate Access Day.
Then, on Thursday, September 20, Dr. Lindsay will present at the Credit Suisse Small and Mid-Cap Conference, starting at 1:50 pm ET and will provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation webcast.
About Sequenom Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
SOURCE Sequenom, Inc.